The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly PR Newswire CHICAGO, June 24, 2013 CHICAGO, June 24, 2013 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Walgreens (NYSE:WAG-Free Report), Express Scripts Holding Company (Nasdaq:ESRX-Free Report), Haemonetics Corporation (NYSE:HAE-Free Report), ResMed Inc. (NYSE:RMD-Free Report) and Eli Lilly and Company (NYSE:LLY-Free Report). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free. Here are highlights from Friday's Analyst Blog: Will Walgreens Miss 3Q Earnings? Walgreens (NYSE:WAG-Free Report) is set to report third-quarter fiscal 2013 results before the opening bell on Tuesday, Jun 25. In the second quarter, this drug retail giant posted a 1.05% positive earnings surprise after two consecutive misses. Let's see how things are shaping up prior to the announcement. Factors to Consider this Quarter As reported earlier, Walgreens' total sales came in at $18.34 in the third quarter of fiscal 2013. Despite sales growth of 3.3% year over year, the quarterly sales trailed the Zacks Consensus Estimate for the fifth time in a row. Nonetheless, the company witnessed higher comparable store sales and front-end comparable store sales. Additionally, comparable pharmacy sales improved in the third quarter. As it crossed the halfway mark of fiscal 2013, things started looking up for Walgreens. Following the reconciliation withExpress Scripts Holding Company (Nasdaq:ESRX-Free Report), Walgreens is sanguine about increasing returns of customers. This is reflected in the higher number of prescriptions filled at the company's comparable stores in the third quarter. Walgreens' timely progress to deliver first-year synergy targets following its Alliance Boots deal in encouraging. Notably, the company's third-quarter numbers will reflect whether its deal-making spree is paying off. However, the generic wave in the pharmaceutical industry continues to hurt revenues. The company also faces tough industry conditions and competitive headwinds. Earnings Whispers? Our proven model does not conclusively show that Walgreens will likely beat earnings estimates this quarter. That is because a stock needs to have both a positive Earnings ESP (Read: Zacks Earnings ESP: A Better Method) as well as a Zacks Rank of #1, 2 or 3 for this to happen. This is not the case here as you will see below. Zacks Earnings ESP: The Most Accurate Estimate stands at $0.90 while the Zacks Consensus Estimate is also at $0.90. This comes to a difference of 0.00%. Zacks Rank #3 (Hold): Walgreens carries a Zacks Rank #3 (Hold), which increases the predictive power of ESP. However, the Zacks Rank #3 when combined with a 0.00% ESP makes surprise prediction difficult. Other Stocks to Consider Here are some other companies you may want to consider as our model shows that these have the right combination of ingredients to post an earnings beat this quarter: Haemonetics Corporation (NYSE:HAE-Free Report), Earnings ESP of +2.13% and a Zacks Rank #1 (Strong Buy) ResMed Inc. (NYSE:RMD-Free Report), Earnings ESP of +4.84% and a Zacks Rank #3 (Hold) Label Updates for Lilly Drugs Eli Lilly and Company (NYSE:LLY-Free Report) and Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that the labels for their diabetes drugs, Tradjenta (linagliptin) and Jentadueto (linagliptin plus metformin) will be updated in the US. Eli Lilly and Boehringer Ingelheim said that the label updates had been approved by the US Food and Drug Administration (FDA). The label updates will provide information needed to ensure the proper use of these medicines by physicians, pharmacists and patients. Eli Lilly and Boehringer Ingelheim said that the Prescribing Information (PI) section of the labels for Tradjenta and Jentadueto will carry additional information regarding the risk of pancreatitis. The Important Limitations of Use sections within the Indications and Usage sections will be updated with the information that both drugs have not been studied in patients with a history of pancreatitis. Moreover, this section will state that it is not known whether patients with a history of pancreatitis will be at a higher risk for the development of pancreatitis while using Tradjenta or Jentadueto. Meanwhile, the Warnings and Precautions section will include information regarding post marketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking linagliptin. The Patient Counseling Information section will also include information about the potential risk and symptoms of pancreatitis. This section of the label carries instructions asking healthcare providers to inform their patients about the potential risks and benefits associated with the use of Tradjenta or Jentadueto. Eli Lilly and Boehringer Ingelheim also said that they will inform physicians prescribing dipeptidyl peptidase 4 (DPP-4) inhibitors and pharmacists about the label update. Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free. About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today. About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros. Get the full Report on WAG - FREE Get the full Report on ESRX - FREE Get the full Report on HAE - FREE Get the full Report on RMD - FREE Get the full Report on LLY - FREE Follow us on Twitter: http://twitter.com/zacksresearch Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 firstname.lastname@example.org http://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumedthat any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein andis subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release. SOURCE Zacks Investment Research, Inc. Website: http://www.zacks.com
The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly
Press spacebar to pause and continue. Press esc to stop.